Tuesday, May 21, 2013
Tuesday, May 21, 2013

POSTED: Tuesday, May 21, 2013, 9:17 AM
Dr. Gary Gibbons directs the National Heart, Lung and Blood Institute at the National Institutes of Health.

You think you got money problems?

Get in line.

Gary Gibbons graduated from, and worked at, very fancy schools and medical facilities, but he understands that some folks in America face different challenges because the places they live in are challenging. It doesn't relieve anyone of personal responsibility, but there are different challenges.

POSTED: Monday, May 20, 2013, 10:13 AM

  Pennsylvania Sen. Bob Casey says he spends a lot of time pushing for funding of the National Institutes of Health because it translates into jobs in Philadelphia and other parts of this region.

"There is bipartisan consensus, less so on financial levels, but we're not as far apart as we are on other issues," Casey said in a meeting Friday with Inquirer reporters and editors. "I focus on [NIH funding] for a couple reasons. No. 1 is because this region of the country has made great progress but also there is no region more at risk than Southeastern Pennsylvania because of the dollars the state gets."

A Scranton Democrat, Casey said breakthroughs in medical and life sciences research happened in Philadelphia and the surrounding area because of expertise, but also because NIH funding helps pay for the expertise.

POSTED: Friday, May 17, 2013, 9:32 AM

Ranbaxy Laboratories, Ltd., is an India-based pharmaceutical company with a U.S. subsidiary, Ranbaxy USA Inc., headquartered in Parsippany, N.J.

Ranbaxy provided another example this week that drug companies the world over are sometimes willing to skirt rules and laws, while ignoring public and patient safety.

The Justice Department said Monday that it had reached the largest drug safety settlement to date with a generic drug manufacturer. Ranbaxy agreed to pay $500 million and plead guilty to criminal charges relating to the manufacture and distribution of certain drugs made at two of Ranbaxy’s facilities in India. The Justice Department statement is here.

POSTED: Wednesday, May 15, 2013, 8:45 AM
FILE - Actress Angelina Jolie arrives for the British Gala premiere for the film 'Salt', at a central London cinema, in this Aug. 16, 2010 file photo. Jolie authored an op-ed for Tuesday’s May 14, 2013 New York Times where she writes that in April she finished three months of surgical procedures to remove both breasts as a preventive measure. She says she’s kept the process private but is writing about it now with hopes she can help other women. (AP Photo/Joel Ryan, File) ( Joel Ryan )

Movie star Angelina Jolie's revelation Tuesday of having had a double mastectomy to help avoid breast cancer had business and legal angles.

Myriad Genetics, the Utah-based company at the center of a legal debate about the acceptability of gene patenting, has a monopoly on the testing Jolie had before opting for surgery. With the news of Jolie breaking in the morning, the company's stock rose to a three-year high of $34.70 during trading on the NASDAQ market on  Tuesday. The trading volume was also much higher, with 2.6 million shares exchanged, more than double the three-month daily average of 1.1 million shares.

Jolie explained her decision in an Op-Ed piece in the New York Times, a link to which is here.

POSTED: Tuesday, May 14, 2013, 5:42 AM

Indiana farmer Vaughn Hugh Bowman got shut out at the Supreme Court and some of the cheering from the stands was the biotech industry.

A soybean farmer from Indiana, Bowman took on a giant in the industrialized agriculture world, Monsanto, and lost badly. All nine justices ruled in favor of Monsanto. The case was Bowman v. Monsanto et al., and a link to the opinion is here.

The court will decide several cases this spring that involve patent law and drug companies. Still to come is a decision on human gene patenting and whether generic and brand-name companies violated antitrust laws in settling litigation about patent infringement.

POSTED: Monday, May 13, 2013, 9:22 AM

Malvern-based Endo Health Solutions will be a stock to watch Monday when the stock market opens because of Friday evening's news that the FDA had rejected the company's request to stop generic competitors to Endo's Opana ER opioid painkiller.

The FDA announcement came after the trading closed Friday. But word of the pending announcement leaked out enough that trading was halted Friday before the market closed.

POSTED: Friday, May 10, 2013, 7:49 PM
This undated image made available by Teva Women's Health shows the packaging for their Plan B One-Step (levonorgestrel) tablet, one of the brands known as the "morning-after pill." The Plan B morning-after pill is moving over-the-counter, a decision announced by the Food and Drug Administration just days before a court-imposed deadline. On (AP)

A New York federal judge on Friday gave the go-ahead for women of any age to buy over-the-counter, morning-after oral contraceptives. Plan B is made by Teva Pharmaceutical Industries Ltd., which is based in Israel but has its Americas headquarters in North Wales, Montgomery County. There are also generic versions.

The Associated Press story is below:

By Larry Neumeister

POSTED: Friday, May 10, 2013, 7:01 PM

In a stinging rebuke that will cause financial pain, the U.S. Food and Drug Administration late Friday rejected Malvern-based Endo Health Solutions' request that the agency deny approval to generic versions of its opioid painkiller Opana ER.

Last year, Endo took the unusual step of asking the agency in a citizens petition to withdraw approval of its own drug on safety grounds. Overdose deaths from opioid painkillers now exceed those by cocaine or heroin. Besides swallowing too many pills, abusers crush, liquefy, inject and smoke the drug to get high.

Endo sought approval of a new form of the drug that Endo said was tamper resistant and wanted generics blocked from entering the market. But the FDA dismissed Endo's suggestion that its request was made on safety grounds, viewing it as a way to deter generic competitors.

POSTED: Friday, May 10, 2013, 10:15 AM
Andrew Witty (right), GlaxoSmithKline CEO, and Justin Forsyth, Save the Children CEO, in Kenya with Aisha, 25, and daughter Leila, 5. (Sven Torfinn / Save the Children)

Justin Forsyth changed his mind about GlaxoSmithKline.

Forsyth is the chief executive officer of Save the Children, which announced a five-year, $23 million agreement with GSK to work on improving health care and vaccination in the developing world. One aim is to combat basic-but-deadly problems such as diarrhea, pneumonia and malnutrition for children.

"I used to protest against GSK and campaign against GSK," Forsyth said during a conference call with reporters on from Nairobi. "That was years ago before Andrew Witty took over and it was because the high prices that they were charging for HIV medicine."

POSTED: Thursday, May 9, 2013, 8:29 AM

Drugmakers Merck and GlaxoSmithKline joined the GAVI Alliance in a new agreement to supply HPV vaccine at lower prices to developing countries to help girls and women in those nations avoid cervical cancer.

GAVI stands for the Global Alliance for Vaccines and Immunization and is based in Geneva. It is a public-private partnership, funded by governments and non-profit organizations, with for-profit drug companies contributing medicine at lower prices than they charge in developed countries.

Human papillomavirus can contribute to cancer of the cervix, anus and other parts of the pelvis. Both girls and boys have begun to be treated with the vaccine in the United States and other developed countries.

About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook. Reach David at dsell@phillynews.com.

David Sell
Blog archives:
Past Archives: